Orion Oyj targets pain signals to improve quality of life
Finnish pharmaceutical company Orion Oyj is developing new methods to affect pain signals transmitted to the brain. The company focuses on treating neuropathic pain and pain from osteoarthritis, aiming for safer and more effective solutions.
Helsinki – Orion Oyj, a Finnish pharmaceutical company, is advancing research into new pain relief methods, aiming to enhance the quality of life for individuals suffering from chronic pain. The company's strategic focus is on developing treatments for neuropathic pain and pain associated with osteoarthritis.
Led by Senior Scientist Lauri Louhivuori, Orion's pain research team is working to understand the underlying causes of pain and to find ways to directly influence nerve cells and the transmission of pain signals to the brain. The ultimate goal is to discover treatments that are both highly effective and safe.
The pain research team comprises a diverse group of experts with strong backgrounds in neuroscience. Their work spans the entire drug development process, from the early identification of potential drug targets to preparations for clinical trials. Collaboration extends to specialists in medicinal chemistry, business development, and marketing.
Orion has maintained a commitment to research in central nervous system diseases and pain management, even as other major pharmaceutical firms have reduced their investment in these areas. This sustained focus has reportedly opened doors to new partnership opportunities with leading global research institutions. The company believes it is well-positioned to become a leader in pain research and relief.
The company emphasizes a supportive research environment where new ideas are encouraged and cross-disciplinary collaboration is integral to problem-solving. Orion highlights the importance of teamwork and mutual support among its employees, recognizing these as critical components in the complex journey of drug development.